Format

Send to

Choose Destination
Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363.

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Author information

1
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. amit.bar-or@mcgill.ca

Erratum in

  • Ann Neurol. 2008 Jun;63(6):803. Arnlod, Douglas [corrected to Arnold, Douglas].

Abstract

We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

PMID:
18383069
DOI:
10.1002/ana.21363
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center